CALR and neoplasm: Calreticulin is exposed to the plasma membrane as a DAME in early apoptosis and crosstalks with CD91 receptors in phagocytes, enabling them to ingest dead cells efficiently, resulting in subsequent cross-presentation of tumor antigen and tumor-distinct cytotoxic T lymphocyte responses [59].